您当前的位置:
首页 >
文章列表页 >
The development of 177Lu labelled peptides
REVIEW | 更新时间:2026-03-02
    • The development of 177Lu labelled peptides

    • This article introduces the research progress of 177Lu labeled peptide radiopharmaceuticals in the field of tumor therapy. Experts have explored strategies such as polymerization, dual targeted design, and blood half-life extension modification, providing a key technical path for improving targeted peptide tumor retention.
    • Journal of Radiation Research and Radiation Processing   Vol. 44, Issue 1, Pages: 10102(2026)
    • DOI:10.11889/j.1000-3436.2025-0082    

      CLC: R817.9
    • Received:10 September 2025

      Revised:2026-01-04

      Accepted:04 January 2026

      Published:20 February 2026

    移动端阅览

  • XU Qianlong, LI Fenglin, FENG Hejuan, et al. The development of 177Lu labelled peptides[J]. Journal of Radiation Research and Radiation Processing, 2026, 44(1): 010102. DOI: 10.11889/j.1000-3436.2025-0082. CSTR: 32195.14.j.JRRRP.1000-3436.2025-0082.

  •  
  •  

0

Views

39

下载量

0

CSCD

Alert me when the article has been cited
提交
Tools
Download
Export Citation
Share
Add to favorites
Add to my album

Related Articles

No data

Related Author

No data

Related Institution

No data
0